In a region where a medical appointment can mean hours on the highway, South Texas Blood & Tissue is putting high-end medicine on wheels. The group has rolled out a bus-sized mobile unit built to collect immune cells for advanced cell and gene therapies, moving leukapheresis out of hospitals and closer to patients across South Texas.
The new "Advanced Therapies Bus" is equipped to perform both leukapheresis and stem cell collections on board. It is intended to expand access across thousands of square miles of South Texas, with officials saying the vehicle recorded its first cell donation last October and will begin traveling through the region in the coming months.
BioBridge Global, the San Antonio nonprofit that oversees South Texas Blood & Tissue and BBG Advanced Therapies, published details about the vehicle and its first donation, noting that the mobile center collects the starting material used to create personalized therapies, according to BioBridge Global. Local coverage has also highlighted the unit's reach and capabilities; KSAT reported that the bus serves roughly 63,000 square miles and recorded its first donation in October. Naomi Herrera, a local advocate quoted by KENS5, said the program "aims to eliminate the need for patients or donors to travel to access machines or beds."
How the bus works
"Just like our blood bus in 1974 brought donation opportunities into the community, this vehicle brings cell collections directly to patients," BBG leadership said. According to BioBridge Global, the mobile center mirrors hospital collection setups, with validated apheresis instruments, environmental monitoring and redundant power systems. Inside, there are two collection stations, an onboard testing lab, a wheelchair lift and a lavatory.
The team operating the bus follows FACT-accredited protocols and manages documentation and traceability so that collected cells can be routed into clinical or commercial therapies. In other words, this is not a stripped-down bloodmobile but a rolling extension of a hospital-grade collection site.
Who it will serve
The bus is aimed at communities that previously had to travel long distances for leukapheresis, including the Rio Grande Valley, Laredo, Eagle Pass, Del Rio and Victoria. KSAT reported that the mobile center's service area covers roughly 63,000 square miles, a footprint program leaders say could help boost enrollment of Hispanic and rural patients in clinical trials.
Industry observers note that bringing collection closer to where people live can broaden donor pools and reduce barriers that have kept many patients and healthy volunteers out of cell-therapy research.
Why experts say it matters
Decentralized leukapheresis is seen as a way to cut delays and travel burdens that can prevent patients from receiving CAR T and other cell therapies, which often depend on tightly timed cell collection. As Pharmaceutical Technology reports, the bus was designed with redundant power, environmental monitoring and documentation systems so that collections meet the same quality controls used at fixed sites.
The AABB has highlighted growing industry interest in mobile collection platforms that can support decentralized trials and help scale up cell-therapy supply chains.
Voices from patients and families
For advocates like Naomi Herrera, the bus is a direct response to families who cannot easily travel for care. She told KENS5 that patients or donors sometimes have to decline treatment because they cannot make long trips.
Herrera's daughter Taylor was diagnosed with acute myeloid leukemia and died on April 28, 2019, and Herrera has used that experience to push for easier local access to advanced therapies, according to the same report. Program leaders say the mobile option is meant to add capacity and convenience for patients and healthy donors rather than replace donor registries or fixed collection centers.
What's next
Organizers say the Advanced Therapies Bus will begin visiting partner hospitals and community sites across South Texas in the coming months as routes are finalized. Program staff are promoting the vehicle as a resource for decentralized clinical trials and broader donor recruitment, while community groups say they will be watching to see whether this rolling lab actually closes travel-related treatment gaps.
